A panorama to mine “bioactive X” against progressive deterioration of liver disease: from NAFLD to HCC DOI Creative Commons
Ki‐Kwang Oh, Sang Jun Yoon,

Jung-A Eom

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 8, 2023

Abstract Non-alcoholic fatty liver disease (NAFLD) is implicated in steatohepatitis (NASH), cirrhosis (LC) to hepatocellular carcinoma (HCC), sequentially. Herein, our aim was unravel the nuanced key components (compounds, and targets) deter progressive severity concerning diseases. We incorporated rigor bioinformatics computational screening tools decode effector(s) against NAFLD, NASH, LC, HCC. The targets of four hepatic-diseases were browsed by DisGeNET OMIM, then, intersecting identified Venn diagram. Protein-protein interaction (PPI) networks constructed on STRING database with aid R program. uppermost target(s) HCC filtered degree centrality (DC), betweenness (BC) value. utilized Selleckchem (compound repository website) retrieve ligand(s) for target(s), hereby, confirmed affinity via molecular docking test (MDT), density functional theory (DFT), toxicity prediction. final (295) core PPI comprised 26 nodes, 248 edges two (INS, IL6) highest 30% (BC). corresponding ligands PDX1 (transcription factor INS; one agonist), IL6 (thirty-two antagonists) Selleckchem. Molecular (MDT) revealed that PDX1- BRD7552 conformer (-12.1 kcal/mol), IL6- Forsythoside B (-11.4 kcal/mol) formed most stable complex. In parallel, DFT proposed BRD7552, had significant chemical properties react targets, respectively. conclusion, we decoded causatives web-based drug repositioning theory. as agonist, antagonist attributed synergistic efficacy NAFLD-derived

Language: Английский

Novel Bio-Engineering Techniques for Construction of Next-Generation Monoclonal Antibodies in the Framework of Personalized Medicine DOI Creative Commons

Mahdi Barazesh,

Shiva Mohammadi, Sajad Jalili

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 19, 2024

Monoclonal antibodies (mAbs), belonging to the IgG subclass, are most progressively growing biopharmaceutics with successful applications for remediation of chronic disorders, including tumors, inflammatory diseases, and retinal neovascularization. Several engineered platforms have been developed recently construction new generations these recombinant proteins improved affinity, antibody-dependent cellular cytotoxicity (ADCC) complement-dependent (CDC) function, effector activity, therapeutic properties. These include antibody fusion such as CAR-T CAR-NK cells, immunotoxin, bispecific antibodies, antibody-cytokine, drug-conjugated antibodies. This chapter discusses various bioengineering techniques, focusing on genetic protein engineering methods. Besides, it describes superiority drawbacks technologies monoclonal production by considering stability, effectiveness, bio-safety human applications. There is still potential developing a novel technique that straightforward, rapid, affordable while ensuring stability efficiency biotherapeutic agents in framework personalized medicine. Contribution techniques develop medicine application anticipated through quick generation individual-specific better efficacy, well development combinatorial medications innovative delivery platforms.

Language: Английский

Citations

0
A panorama to mine “bioactive X” against progressive deterioration of liver disease: from NAFLD to HCC DOI Creative Commons
Ki‐Kwang Oh, Sang Jun Yoon,

Jung-A Eom

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 8, 2023

Abstract Non-alcoholic fatty liver disease (NAFLD) is implicated in steatohepatitis (NASH), cirrhosis (LC) to hepatocellular carcinoma (HCC), sequentially. Herein, our aim was unravel the nuanced key components (compounds, and targets) deter progressive severity concerning diseases. We incorporated rigor bioinformatics computational screening tools decode effector(s) against NAFLD, NASH, LC, HCC. The targets of four hepatic-diseases were browsed by DisGeNET OMIM, then, intersecting identified Venn diagram. Protein-protein interaction (PPI) networks constructed on STRING database with aid R program. uppermost target(s) HCC filtered degree centrality (DC), betweenness (BC) value. utilized Selleckchem (compound repository website) retrieve ligand(s) for target(s), hereby, confirmed affinity via molecular docking test (MDT), density functional theory (DFT), toxicity prediction. final (295) core PPI comprised 26 nodes, 248 edges two (INS, IL6) highest 30% (BC). corresponding ligands PDX1 (transcription factor INS; one agonist), IL6 (thirty-two antagonists) Selleckchem. Molecular (MDT) revealed that PDX1- BRD7552 conformer (-12.1 kcal/mol), IL6- Forsythoside B (-11.4 kcal/mol) formed most stable complex. In parallel, DFT proposed BRD7552, had significant chemical properties react targets, respectively. conclusion, we decoded causatives web-based drug repositioning theory. as agonist, antagonist attributed synergistic efficacy NAFLD-derived

Language: Английский

Citations

0